The newly launched Merck Lumira Biosciences Fund has held its first closing at $43m.
The investment vehicle was establised by Global health care leader Merck (which has made a $35m investment) in collaboration with Lumira Capital, Teralys Capital and other partners.
The fund, which is targeting $50m, will provide capital to support early stage life science innovation in Québec, Canada.
It will be managed by Lumira Capital.
FinSMEs
29/03/2012